Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes

对人类针对埃博拉病毒糖蛋白的抗体反应进行系统分析表明,中和性公共克隆型的流行率很高。

阅读:2
作者:Elaine C Chen ,Pavlo Gilchuk ,Seth J Zost ,Philipp A Ilinykh ,Elad Binshtein ,Kai Huang ,Luke Myers ,Stefano Bonissone ,Samuel Day ,Chandrahaas R Kona ,Andrew Trivette ,Joseph X Reidy ,Rachel E Sutton ,Christopher Gainza ,Summer Diaz ,Jazmean K Williams ,Christopher N Selverian ,Edgar Davidson ,Erica Ollmann Saphire ,Benjamin J Doranz ,Natalie Castellana ,Alexander Bukreyev ,Robert H Carnahan ,James E Crowe Jr

Abstract

Understanding the human antibody response to emerging viral pathogens is key to epidemic preparedness. As the size of the B cell response to a pathogenic-virus-protective antigen is poorly defined, we perform deep paired heavy- and light-chain sequencing in Ebola virus glycoprotein (EBOV-GP)-specific memory B cells, allowing analysis of the ebolavirus-specific antibody repertoire both genetically and functionally. This approach facilitates investigation of the molecular and genetic basis for the evolution of cross-reactive antibodies by elucidating germline-encoded properties of antibodies to EBOV and identification of the overlap between antibodies in the memory B cell and serum repertoire. We identify 73 public clonotypes of EBOV, 20% of which encode antibodies with neutralization activity and capacity to protect mice in vivo. This comprehensive analysis of the public and private antibody repertoire provides insight into the molecular basis of the humoral immune response to EBOV GP, which informs the design of vaccines and improved therapeutics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。